12 Best Long Term Low Risk Stocks to Buy Right Now
As the DeepSeek craze ignites a sell-off in the tech sector, investors are weighing the implications of the downturn in the long term.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
EMA panel backs Bristol Myers' Opdivo-Yervoy for liver cancer
PRINCETON, N.J. - Bristol Myers Squibb (NYSE: BMY), a prominent pharmaceutical company with a market capitalization of nearly $120 billion and impressive gross profit margins of 76%, received a ...
Bristol Myers gets positive CHMP opinion for Opdivo plus Yervoy
Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended ...
Bristol Myers’ Breyanzi receives positive CHMP opinion in follicular lymphoma
Bristol Myers (BMY) announced the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has ...
Bristol-Myers Squibb: Too Valuable Not To Hold This Pharma Gem, But Debt Challenges Remain
Bristol-Myers Squibb gets rated a hold, as I see future value in its clinical portfolio and pipeline, particularly ...
Barchart on MSN8h
What Are Wall Street Analysts' Target Price for Bristol-Myers Squibb Stock?
Bristol-Myers Squibb Company (BMY) is one of the leading biopharmaceutical companies focused on developing treatments for ...
Bristol-Myers Squibb (NYSE:BMY) Price Target Raised to $65.00
Bristol-Myers Squibb (NYSE:BMY – Free Report) had its target price boosted by Citigroup from $60.00 to $65.00 in a report published on Tuesday,Benzinga reports. They currently have a neutral rating on ...
London open: FTSE edges up ahead of US inflation reading; Smiths Group surges
Fashion and homeware retailer Next jumped to the top of the FTSE 100 after an upgrade to 'buy' from 'neutral' at UBS, which said the company was at an "inflection point" when it comes to growth and ...
Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?
Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.